Business Description
Roivant Sciences Ltd
ISIN : BMG762791017
Share Class Description:
FRA:87S: Ordinary SharesTotal Employee Number:
721Description
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 39.95 | |||||
Equity-to-Asset | 0.79 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.08 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Altman Z-Score | 36.07 | |||||
Beneish M-Score | -3.58 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -35.2 | |||||
3-Year EBITDA Growth Rate | -18.6 | |||||
3-Year EPS without NRI Growth Rate | -9.3 | |||||
3-Year FCF Growth Rate | 3.1 | |||||
3-Year Book Growth Rate | 60.4 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 462.77 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 78.23 | |||||
9-Day RSI | 75.1 | |||||
14-Day RSI | 71.22 | |||||
3-1 Month Momentum % | 7.33 | |||||
6-1 Month Momentum % | 40.06 | |||||
12-1 Month Momentum % | 168.39 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 18.37 | |||||
Quick Ratio | 18.37 | |||||
Cash Ratio | 15.26 | |||||
Days Sales Outstanding | 29.96 | |||||
Days Payable | 4635.7 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 1.8 | |||||
Shareholder Yield % | 0.73 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 84.44 | |||||
Operating Margin % | -15560.57 | |||||
Net Margin % | -3629.19 | |||||
EBITDA Margin % | -15520.04 | |||||
FCF Margin % | -9174.6 | |||||
OCF Margin % | -9075.23 | |||||
ROE % | -6.75 | |||||
ROA % | -5.66 | |||||
ROIC % | -189.11 | |||||
3-Year ROIIC % | -94.51 | |||||
ROC (Joel Greenblatt) % | -1254.38 | |||||
ROCE % | -25.07 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 2839.17 | |||||
PB Ratio | 5.42 | |||||
Price-to-Tangible-Book | 5.42 | |||||
EV-to-EBIT | -16.41 | |||||
EV-to-EBITDA | -16.45 | |||||
EV-to-Revenue | 2552.81 | |||||
EV-to-Forward-Revenue | 1387.68 | |||||
EV-to-FCF | -27.8 | |||||
Price-to-GF-Value | 3.26 | |||||
| Price-to-Net-Current-Asset-Value | 6.16 | |||||
| Price-to-Net-Cash | 7.9 | |||||
Earnings Yield (Greenblatt) % | -6.09 | |||||
FCF Yield % | -3.1 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Roivant Sciences Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 7.106 | ||
| EPS (TTM) (€) | -0.514 | ||
| Beta | 1.0048 | ||
| 3-Year Sharpe Ratio | 1.03 | ||
| 3-Year Sortino Ratio | 1.86 | ||
| Volatility % | 45.96 | ||
| 14-Day RSI | 71.22 | ||
| 14-Day ATR (€) | 0.733145 | ||
| 20-Day SMA (€) | 26.057 | ||
| 12-1 Month Momentum % | 168.39 | ||
| 52-Week Range (€) | 8.982 - 30.36 | ||
| Shares Outstanding (Mil) | 719.27 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Roivant Sciences Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Roivant Sciences Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2027 | 2026-11-10 08:00 | In 135 days | ||
| Second quarter earnings results for 2027 | 2026-11-10 | In 134 days | ||
| General meeting for 2026 | 2026-09-10 09:30 | In 74 days | ||
| First quarter earnings conference call for 2027 | 2026-08-11 08:00 | In 44 days | ||
| First quarter earnings results for 2027 | 2026-08-11 | In 43 days | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 11:20 | 24.18 (+0.46%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 14:00 | 24.46 (-0.57%) | ||
| Fourth quarter earnings conference call for 2026 | 2026-05-20 08:00 | 24.47 (+1.07%) | ||
| Annual report for 2026 | 2026-05-20 | 24.47 (+1.07%) | ||
| Fourth quarter earnings results for 2026 | 2026-05-20 | 24.47 (+1.07%) |
Show
Entries
Roivant Sciences Ltd Frequently Asked Questions
What is Roivant Sciences Ltd(FRA:87S)'s stock price today?
The current price of FRA:87S is €29.53. The 52 week high of FRA:87S is €30.36 and 52 week low is €8.98.
When is next earnings date of Roivant Sciences Ltd(FRA:87S)?
The next earnings date of Roivant Sciences Ltd(FRA:87S) is 2026-08-11 Est..
Does Roivant Sciences Ltd(FRA:87S) pay dividends? If so, how much?
Roivant Sciences Ltd(FRA:87S) does not pay dividend.
Press Release
Articles on Roivant Sciences Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers